Category Archives: osteoporosis

Are you at risk for the complications due to ankylosing spondylitis? Discover what they are…

Ankylosing spondylitis (AS) is an inflammatory form of arthritis that preferentially attacks the spine.  Many people are under the impression it’s one of the less serious forms of arthritis. Uh-uh.  Unfortunately, it has a number of potential complications associated with it.  These include:

  1. Acute eye inflammation, termed “uveitis”, in one-third of patients.  Symptoms include pain, redness, blurred vision, light sensitivity, and if left untreated, blindness.
  2. Osteoporosis occurring in a significant number of patients.  This is a condition where the bones become brittle and more likely to fracture.
  3. Approximately 10-15% of patients have inflammatory bowel disease such as Crohn’s or ulcerative colitis.
  4. Skin involvement occurs in as many as a quarter of patients.  The most common skin condition is psoriasis.
  5. AS can lead to conduction abnormalities in the heart as well as inflammation of the aorta.
  6. Fibrosis of the lungs can cause restrictive lung disease.
  7. Neurologic complications are due to compression of the spinal cord and can be life-threatening.
  8. Long term ankylosing spondylitis can cause a condition called amyloidosis of the kidneys leading to kidney failure.

Comment: Not such a benign condition is it?

For more information on arthritis treatments and other arthritis problems,  go to:

Arthritis Treatment

And don’t forget to sign up for  free weekly arthritis tips and a free copy of our special report “The Consumer’s Guide to Arthritis”

Just go here Contact

Osteoporosis Drugs May Benefit Patients With Knee Osteoarthritis

Lynda Williams writing in Medwire reported, “Research adds weight to reports that patients with knee osteoarthritis may experience benefits in pain or progression relief from bisphosphonate treatment.”

osteoarthritis-knee-2Bisphosphonates are drugs typically used to treat osteoporosis.osteoporosis Investigators who analyzed “data from the National Institutes of Health Osteoarthritis Initiative cohort shows that patients who used bisphosphonates  for 3 or more years over a 5-year period achieved a significant reduction in rating scale pain scores at years 2 and 3 compared with nonusers, after adjusting for baseline levels of pain and analgesic use.”

The findings were published in the Annals of Rheumatic Diseases.

Comment: Killing two birds with one stone…

 

For more information on arthritis treatments and other arthritis problems,  go to:

Arthritis Treatment

And don’t forget to sign up for  free weekly arthritis tips and a free copy of our special report “The Consumer’s Guide to Arthritis”

Just go here Contact

New Osteoarthritis Drug Slows Cartilage Wear?

The Holy Grail for osteoarthritis treatment is a disease modifying osteoarthritis drug.  This article talks about one possibility.

Kevin Deane writing in MedScape reported on a study from Belgium published in the Annals of Rheumatic Diseases. In this randomized, double-blind, placebo-controlled trial, called SEKOIA, Yves Reginster and colleagues used strontiumstrontium ranelate at either 1 or 2 g daily compared with placebo in 1371 patients with grade 2 or 3 knee osteoarthritis, as defined by Kellgren and Lawrence, with a joint space width of 2.5-5 mm. Patients were followed for 3 years, and outcomes included x-ray changes in joint space width, overall health related to osteoarthritis as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, and pain as measured on a visual analog scale.

Treatment with strontium ranelate at a daily dose of 1 or 2 g was associated with a statistically smaller reduction in joint space width on plain x-rays. Treatment with the 2-g/day dose was also associated with improved health status related to osteoarthritis, as measured by the overall WOMAC score (P = .045) and a WOMAC subscore of pain (P = .028). The WOMAC subscore for physical function and knee pain as measured by the visual analog scale trended toward improvement in patients treated with the 2-g/day dose but did not reach statistical significance.

Reginster and colleagues concluded that treatment with strontium ranelate at daily doses of 1 or 2 g is associated with a significant reduction in progression of radiographic joint space width, and at 2 g/day with an effect on overall health associated with osteoarthritis.

Comment: Strontium may be effective.  It is already used to treat osteoporosis in Europe.  However, it has potential side effects including: deep vein thrombosis and a potentially fatal skin condition called Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome)

For more information on arthritis treatments and other arthritis problems,  go to:

Arthritis Treatment

And don’t forget to sign up for  free weekly arthritis tips and a free copy of our special report “The Consumer’s Guide to Arthritis”

Just go here Contact